Gladstone Institutional Advisory’s Ginkgo Bioworks DNA Stock Holding History

Gladstone Institutional Advisory’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-356	Closed	-$24.1K	–	668
2022 Q4	$24.1K	Hold	356	–	–	﹤0.01%	635
2022 Q3	$44K	Hold	356	–	–	﹤0.01%	622
2022 Q2	$34K	Hold	356	–	–	﹤0.01%	637
2022 Q1	$57K	Hold	356	–	–	﹤0.01%	689
2021 Q4	$118K	Sell	356 -7,013	-95%	-$3.33M	0.01%	577
2021 Q3	$3.42M	Buy	+7,369	New	+$3.59M	0.33%	79

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Gladstone Institutional Advisory's DNA Position: Q1 2023 in Review

Gladstone Institutional Advisory sold out of Ginkgo Bioworks (DNA) in Q1 2023, closing a stake of 356 shares — an estimated $24.1K sold.

Gladstone Institutional Advisory first reported a position in DNA in Q3 2021 and held it in 6 quarters. The position peaked at $3.42M in Q3 2021. 313 funds tracked by Wall St. Rank hold DNA as of Q1 2023.

Gladstone Institutional Advisory reported no remaining Ginkgo Bioworks position as of Q1 2023 after selling out during the quarter.
Gladstone Institutional Advisory sold 356 Ginkgo Bioworks shares in Q1 2023, an estimated $24.1K.
Gladstone Institutional Advisory first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 6 quarters.
Gladstone Institutional Advisory's Ginkgo Bioworks position peaked at $3.42M in Q3 2021.
313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2023.

Based on Gladstone Institutional Advisory's 13F filing for Q1 2023, filed 12 May 2023.